Commentary: 'Healthcare Professionals' Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease' by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519

Authors :: Harma Alma
Corina de Jong
Janwillem Kocks
Thys van der Molen
Groningen Research Institute for Asthma and COPD (GRIAC)
Source :: Frontiers in Pharmacology, 11:827. Frontiers Media SA, Frontiers in Pharmacology, Vol 11 (2020)
Publication Year :: 2020
Publisher :: Frontiers Media SA, 2020.

Subjects :: Pharmacology
medicine.medical_specialty
COPD
Health professionals
business.industry
(MCID) minimal clinically important difference
lcsh:RM1-950
Pulmonary disease
health status
medicine.disease
St. George’s Respiratory Questionnaire
lcsh:Therapeutics. Pharmacology
patient-reported outcomes
medicine
Pharmacology (medical)
Intensive care medicine
business

Tools